TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
stocks
The World Cup stock you’ve never heard of
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 6.60 | 0.07% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,449.31 | 187.70 | -0.36% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 24,213.72 | 38.60 | 0.16% |
| NASDAQ | 25,829.42 | 452.19 | -1.72% |
| Nikkei 225 | 67,242.73 | 1,315.00 | -1.92% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,508.49 | 66.90 | -0.88% |
| S&P/ASX 200 | 8,808.50 | 11.70 | 0.13% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |